



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

## Posaconazole - Medicare

**Phone: 215-991-4300**

**Fax back to: 866-371-3239**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE:** Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached **WILL** delay the review process.

<b>Member Name:</b>	<b>Prescriber Name:</b>	
Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Line of Business: <input type="checkbox"/> Medicare Advantage	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	<b>Specialty/facility name (if applicable):</b>	

**REQUEST FOR EXPEDITED REVIEW:** By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

**Please attach any pertinent medical history including labs and information for this member that may support approval.**

**Please answer the following questions and sign.**

Q1. Is documentation attached showing use for prophylaxis of invasive Aspergillus and Candida infections in severely immunocompromised patients (hematopoietic stem cell transplant (HSCT) recipients with graft-versus host-disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy)? If YES, go to 7. If NO, go to 2.

Yes

No

Q2. Is the request for posaconazole delayed release tablet? If YES, go to 4. If NO, go to 3.

Yes

□ No

Q3. Is the request for posaconazole suspension? If YES, go to 5.

Yes

No

Q4. Is documentation attached showing use for the treatment of invasive aspergillus? If YES, go to 8.

Yes

No

Q5. Is the medication being used for treatment of oropharyngeal candidiasis (OC)? If YES, go to 6.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**MEDICARE ADVANTAGE  
PRIOR AUTHORIZATION REQUEST FORM**

**Posaconazole - Medicare**

**Phone: 215-991-4300**

**Fax back to: 866-371-3239**

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

**PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.**

<b>Member Name:</b>	<b>Prescriber Name:</b>
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q6. For OC, is documentation attached showing inadequate response, intolerance, or contraindication to itraconazole or fluconazole? If YES, go to 8.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q7. Is the patient 2 years of age or older? If YES, go to 9.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q8. Is the patient 13 years of age or older? If YES, go to 9.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q9. Does the patient have a known hypersensitivity to posaconazole or other azole antifungal agents?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q10. Will posaconazole be used with sirolimus, CYP3A4 substrates (pimozide, quinidine), HMG-CoA reductase inhibitors primarily metabolized through cyp3a4 (e.g., atorvastatin, lovastatin, and simvastatin), ergot alkaloids (ergotamine and dihydroergotamine), or venetoclax?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q11. Requested Duration:	
<input type="checkbox"/> 12 Months	<input type="checkbox"/> Other:
Q12. Additional Information:	

\_\_\_\_\_  
Prescriber Signature

\_\_\_\_\_  
Date

v2026